A P R I L 2 0 0 1 113 Transient expression of the tumor suppressor gene p53 via adenoviral-mediated gene transfer induces apoptosis in glioma cells expressing mutant p53, while causing cell cycle arrest in cells with wild-type p53. To determine whether a change in p53 status of a wild-type p53-expressing cell line such as U-87 MG would alter its apoptotic resistant phenotype in response to Ad-p53 infection, we generated cell lines U-87-175.4 and U-87-175.13 via retroviral-mediated gene transfer of the p53 (175H) mutant into the U-87 MG parental line. Control cell lines U-87-Lux.6 and U-87-Lux.8 were also generated and express the reporter gene luciferase. Both U-87-175.4 and U-87-175.13, but not control cell lines, exhibited morphology characteristic of apoptosis after Ad-p53 infection. Furthermore, expression of other p53 mutants (248W, 273H) in U-87 MG also sensitized cells to Adp53-induced apoptosis. Apoptosis was con rmed by TUNEL and cell cycle analysis. Several p53 response genes were examined in cells infected with Ad-p53, and among these, BCL2, p21 WAF1/CIP1 , CPP32/caspase 3, and PARP showed differences in expression between U87-175 and U87-Lux cell lines. Taken together, our data demonstrate that the introduction of p53 mutants in U-87 MG promotes an apoptotic response in association with adenoviral-mediated wild-type p53 gene transfer. These results underscore the importance of glioma p53 genotype for predicting tumor response to p53-based gene therapy. Neuro-Oncology 3, 113-122, 2001 (Posted to NeuroOncology [serial online], Doc. 00-043, February 20, 2001 The p53 tumor suppressor gene is a nuclear phosphoprotein that transcriptionally regulates the expression of a number of target genes including p21 WAF1/CIP1 (el-Deiry et al., 1993) , GADD45 (Hollander et al., 1993) , BAX (Miyashita and Reed, 1995) , and FAS/APO1 (OwenSchaub et al., 1995). In normal cells, the p53 protein is expressed at low levels and has a short half-life due to a rapid turnover rate mediated by ubiquitination and proteolysis. Upon exposure to a number of stressful stimuli, including DNA-damaging agents and hypoxia (Carmeliet et al., 1998) , the p53 protein is stabilized and, in turn, regulates biological functions including cell cycle arrest (elDeiry et al., 1994), apoptosis (Liu et al., 1995) , senescence (Sugrue et al., 1997) , differentiation, and antiangiogenesis (Dameron et al., 1994) . However, p53 function is often deregulated or impaired after the occurrence of mutations or deletions resulting from neoplastic transformation.
The p53 tumor suppressor gene is a nuclear phosphoprotein that transcriptionally regulates the expression of a number of target genes including p21 WAF1/CIP1 (el-Deiry et al., 1993) , GADD45 (Hollander et al., 1993) , BAX (Miyashita and Reed, 1995) , and FAS/APO1 (OwenSchaub et al., 1995) . In normal cells, the p53 protein is expressed at low levels and has a short half-life due to a rapid turnover rate mediated by ubiquitination and proteolysis. Upon exposure to a number of stressful stimuli, including DNA-damaging agents and hypoxia (Carmeliet et al., 1998) , the p53 protein is stabilized and, in turn, regulates biological functions including cell cycle arrest (elDeiry et al., 1994) , apoptosis (Liu et al., 1995) , senescence (Sugrue et al., 1997) , differentiation, and antiangiogenesis (Dameron et al., 1994) . However, p53 function is often deregulated or impaired after the occurrence of mutations or deletions resulting from neoplastic transformation.
Astrocytomas and glioblastomas are the most frequently occurring CNS tumors of neuro-epithelial origin and the most challenging brain tumors to treat. In more than 30% of astrocytomas, mutations exist in the p53 tumor suppressor gene whereby inactivation occurs through missense mutation or loss of heterozygosity (Van Meir et al., 1994) . The p53 gene (located on chromosome 17) is frequently associated with the loss of 1 allele in malignant gliomas, although a large number of malignant gliomas have no p53 mutations (Fults et al., 1992) . Some of the latter tumors have an ampli ed MDM2 (murine double minute 2) gene (He et al., 1994 ) that suppresses p53 gene activity. Both the loss of normal p53 function and the acquisition of oncogenic functions by mutant p53 proteins may contribute to tumorigenesis. Consistent with the de nition of a tumor suppressor gene, the reintroduction of wild-type p53 into many tumor cell lines, including gliomas, results in the activation of cell cycle arrest and/or apoptosis (Gomez-Manzano et al., 1996) . The general conclusion from these studies is that the introduction of wild-type p53 into neoplastic cells in vitro is lethal in most cases, so long as the cells are p53 mut or p53 null . However, the reintroduction of wild-type p53 into p53 wt tumor cells results solely in cell cycle arrest (Nielsen and Maneval, 1998) . The molecular mechanisms underlying the differential response of these cell lines to exogenous p53 remains unclear.
The current phase I clinical trial using Ad-p53 3 to treat glioma is based on laboratory studies in which Adp53 ef ciently suppresses the growth of tumor cells bearing a mutant p53 both in vitro and in vivo (Gomez-Manzano et al., 1996) . However, given the fact that most tumors are heterogeneous in nature, and the ability of exogenous p53 to affect only tumor cells harboring mutant p53, it is conceivable that the sole use of Ad-p53 for the treatment for cancer patients would not yield a satisfactory outcome. Under this notion, it is imperative to investigate the mechanism whereby cells with different p53 gene status respond differently to Ad-p53.
Introduction of mutant p53 (175H) into the wild-type p53 glioblastoma cell line U-87 MG confers a dominant negative phenotype (Yount et al., 1996) . When synchronized cells were irradiated in G 1 , the control cell line (U87-Lux.8) expressing functional p53 was twice as sensitive to radiation as the isogenic dominant negative mutant derivative (U87-175.4), in which p53 was inactivated. Here we have investigated the apoptotic response of the U87-175 cell lines as well as other isogenic cell lines expressing different mutant p53 genes (248W or 273H) after adenoviral-mediated gene transfer of wildtype p53. Our ndings demonstrate that the presence of mutant p53 is a major determinant in whether cells are responsive to Ad-p53 induced apoptosis.
Materials and Methods

Cell Lines
Both U87-Lux.8 and U87-175.4 were derived from the human glioblastoma cell line U-87 MG after recombinant retroviral infection and clonal selection in 400 mg/ml of G418 selection media. Both U87-Lux.8 and U87-175.4 cell lines were generated by infection of U-87 MG with recombinant retrovirus containing a mutant p53 cDNA in codon 175H or a luciferase reporter gene, respectively (Hsiao et al., 1994) . Isogenic cell lines of U-87 MG containing other p53 mutants (248W or 273H) (Zhang et al., 1993) were generated by stable transfection with either pRc/CMV-248W or pRc/CMV-273H expression vector. After G418 selection, colonies were isolated and the expression of p53 was assessed by Western blot analysis. Control cell lines were generated by transfection of only the expression vector pRc/CMV into U-87 MG and similarly selected. Cells were cultured in Dulbecco's modi ed Eagle's/F12 medium (1:1, vol/vol) containing 10% fetal bovine serum supplemented with penicillin and streptomycin. Cells were maintained in a humidi ed atmosphere containing 5.0% CO 2 at 37°C.
Generation of Recombinant Adenovirus and Conditions of Infection
The recombinant p53 adenovirus (Ad-p53) and Ad-b gal contain the cytomegalovirus promoter, wild-type p53 cDNA or b -galactosidase, and SV40 polyadenylation signal in a mini-gene cassette inserted into the E1-deleted region of modi ed adenovirus type 5 (Ad5) (Liu et al., 1995) . Replication-defective adenovirus AdDE1 (provided by Dr. Bingliang Fang (Department of Thoracic and Cardiovascular Surgery, M.D. Anderson Cancer Center, Houston, Tex.) was generated by cotransfecting the pXCJL-1 and pJM 17 plasmids Ad-p53 and AdDE1 (Liu et al., 1999) . The cell lines were infected as previously reported (Gomez-Manzano et al., 1996) , and culture medium was used for mock infection. Infection was performed at 100 MOI for 1 h of incubation at 37°C with constant shaking.
Western Blot Analysis and Antibodies
Total cell lysates were prepared at various time points from mock-infected cells and cells infected with Ad-p53 or AdDE1 virus. Cell pellets were washed in PBS and resuspended with Lysis buffer (150 mM NaCl, 1% Triton X-100, 1.0% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 20 mM EDTA, and 50 mM Tris, pH 7.4) for 30 min on ice. Protein concentrations were determined using the Bradford protein assay (Bio-Rad Laboratories, Richmond, Calif.). Fifty micrograms of protein were subjected to gel electrophoresis and separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After separation, proteins were transferred to a nitrocellulose membrane and blotted with either anti-p53 DO-I, Ab-3 (pAb240; Oncogene Science, Mineola, N.Y.), anti-p21 WAF1/CIP1 (Santa Cruz Biotechnology, Santa Cruz, Calif.), anti-BAX, anti-BCL-X L , anti-MDM2, anti-BCL2, or anti-pro-CPP32 antibodies (Santa Cruz Biotechnology). For PARP detection, cells were sonicated on ice for 20 s and stored in -20°C. Lysates were incubated at 65°C for 15 min prior to gel loading. One hundred micrograms of protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel analysis and was probed with an anti-PARP C2-10 monoclonal antibody at a dilution of 1:2000. Equal loading was determined by using an antiactin antibody (Amersham Corp., Arlington Heights, Ill.).
Cell Viability Assay
Cell cultures were harvested with 0.05% trypsin and seeded in triplicate at 1 3 10 5 in 6-well culture plates for 24 h prior to viral infection. Cells were infected with Adp53 or AdDE1 at 100 MOI. Culture medium was used for mock infection. Cell populations were counted at various time points after infection. Cell viability was assessed by trypan blue (0.1%) exclusion.
Caspase Activity Assay
Cells (1.0-2.0 3 10 6 ) were scraped, washed in PBS, and lysed using 25-50 ml of cell lysis buffer (RandD Systems, Minneapolis, Minn.) to obtain cell lysates. Each enzymatic reaction was performed using 100 mg total protein and was carried out in a at-bottom 96-well plate. Five microliters of the caspase uorogenic substrate was added to each reaction and samples were incubated at 37°C for 1 to 2 h. Fluorescence was measured on a microplate reader using a lter that allowed a light excitation at 400 nm and light collection at 505 nm (Perkin Elmer, Norwalk, Conn.). Substrate for each caspase is as follows: caspase-1, WEHD-AFC; caspase-2, VDVAD-AFC; and caspase-3, DEVD-AFC.
Flow Cytometry
Cells were infected with 100 MOI of Ad-p53 or replication-defective virus AdDE1. They were harvested at 48 h and 96 h postinfection, and pellets were washed 3 times in PBS and xed with 70% ethanol for 24 h at -20 C°. The cells were then stained with a solution of PBS containing 1.0% propidium iodide for 20 min at 37°C to measure DNA content. Flow cytometry of cell cycle proles was performed on an EPICS (I) Pro le Analyzer (Coulter Corp., Hialeah, Fla.).
TUNEL Assay
The assay was performed according to the manufacturer's procedure (Phoenix Flow Systems, San Diego, Calif.). Brie y, after xation and washing, cells were resuspended in 50 ml of TdT buffer containing 0.2 M sodium cacodylate (pH 7.0), 2.5 mM Tris-HCl, 2.5 mM CoCl 2 (Sigma Chemical Company, St. Louis, Mo.), 0.1 mM DTT (Sigma), 0.25 mg/ml bovine serum albumin (Sigma), 5 units of terminal transferase (Boehringer Mannheim Biochemicals, Indianapolis, Ind.), and 0.5 nmol biotin-16-dUTP along with dATP, dGTP, and dCTP at a concentration of 20 mM. Controls were prepared by incubating a separate aliquot of each test sample without dUTP. The cells were incubated in the solution at 37°C for 30 min, rinsed in PBS, and resuspended in 100 ml uorescein isothyocyanate staining solution containing 4X saline-sodium cytrate, 0.1% Triton X-100, and 2.5 mg/ml uoresceined avidin (Vector, Burlingame, Calif.). Tubes were incubated for 30 min in the dark at room temperature. Cells were rinsed in PBS with 0.1% Triton X-100 and resuspended in 0.5 ml PBS containing propidium iodide (5 mg/ml) and 70 ml (1 mg/ml) RNAse. Tubes were incubated in the dark on ice for 30 min prior to ow cytometric analysis.
Results
In Vitro Growth Suppression of Isogenic Mutants as a Result of Transient p53 Expression
To investigate the biological effect of wild-type p53 in glioma cells that differ in their p53 status, we infected isogenic cell lines U87-175.4 and U87-Lux.8 with Adp53 virus. Comparable transduction ef ciency was observed in these cell lines after Ad-b gal reporter virus infection (data not shown). After Ad-p53 infection, U87-Lux.8 displayed morphology characteristically observed in senescence including at, multinucleated cells. This behavior was similar to that which has been reported for U-87 MG cells infected with Ad-p53 (Gomez-Manzano et al., 1996) . In contrast, a signi cant percentage of rounded, dead cells and cell membrane blebbing indicative of apoptosis was observed in U87-175.4 cultures after Ad-p53 infection (Fig. 1) . Moreover, elevated levels of p53 in U87-175.4 cells led to a signi cant (P < 0.001) reduction in cell viability (Fig. 2) . No features of apoptosis were evident in mock-infected U87-Lux.8 or U87-175.4 cells nor in cells infected with AdDE1, a replication-defective virus void of E1 and E3 genes. Although trypan blue exclusion results indicated similar degrees of cell viability in AdDE1 infection control for both cell lines, some cytotoxicity was noted in AdDE1-infected cultures compared with mock control. The apparent decrease in cell number can be attributed to growth suppression and not to cell death, as later determined by ow cytometry.
Growth Suppression as a Consequence of Apoptosis
Cell cycle analysis was performed using ow cytometry, and the sub-diploid (sub-G 1 ) population was measured as an indication of apoptosis. A time-dependent increase in the sub-G 1 population of Ad-p53-infected U87-175.4 cells was observed, as it escalated to 60.9% by 96 h postinfection. In contrast, no signi cant increase was evident in U87-Lux.8 cells infected with Ad-p53 (Table 1 and Fig. 3 ). These results correlate with cell viability measurements after Ad-p53 infection. Interestingly, a high percentage of cells in G 1 was detected in both cell lines before Ad-p53 infection. This can be attributed to slow cell growth rates previously recorded by Cell Titer 96AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wis.) (data not shown). Cell cycle analysis of U87-Lux.8 cells after Ad-p53 infection resembled that of infected U-87 MG (Gomez-Manzano et al., 1997) . Both cell lines undergo a G 1 arrest postinfection; however, a small population of U87-Lux.8 cells resumes cycling at 96 h (Table 1) . In contrast, U87-175.4 cells infected with Ad-p53 exhibited no build-up in G 2 /M before undergoing apoptosis. The cell cycle distribution of U87-175.4 cells is unlike that of the control cell line U87-Lux.8. Cells infected with AdDE1 virus experienced a background level of cytotoxicity often associated with adenoviral infections. However, ow cytometry and morphologic evidence portray healthy growing cells and indicate that minimal cell death present in control infections was not a result of apoptosis.
To examine whether acute levels of p53 have a generalized effect on other U87-175 transfectants, we performed TUNEL assays on cell lines U87-Lux.6, U87-Lux.8, U87-175.4, and U87-175.13. Results shown in Table 2 demonstrated that a higher percentage of TUNEL-positive cells was detected in both isogenic mutant cell lines than in the control cell lines after Adp53 infection for different time intervals. Some toxicity was noted in U87-Lux.6 cells infected with AdDE1.
Taken together, these results suggested that the introduction of mutant p53 (175H) into a cell line containing a wild type p53 resulted in a generalized apoptotic-sensitive phenotype in response to Ad-p53 infection. It is noteworthy that both U87-175.4 and U87-175.13 cell lines exhibited a high rate of spontaneous apoptosis of 8.6% and 7.1%, respectively, as detected in 72 h post-Ad-p53 infection.
To test the ability of other p53 mutants in sensitizing U-87 MG to Ad-p53-induced apoptosis, 2 additional isogenic p53-mutant cell lines overexpressing a mutant p53 (248W or 273H) were generated. Twenty different clones from each mutant construct were isolated and analyzed for p53 expression by Western blot analysis (data not shown). Based on Western blot analysis, 2 clonal cell lines expressing highest levels of p53, U87-248-1, and U87-273-D, as well as a cell line U87C expressing an empty vector, were infected with 100 MOI of Ad-p53. DNA content and cell cycle pro les were determined by propidium iodide staining and uorescence-activated cell sorting analysis. Both cell lines exhibited an increase in the percentage of sub-G 1 population after Ad-p53 infection (Table 3) . These results suggest that at least 3 different p53 mutants can sensitize wildtype p53-expressing cells to Ad-p53-induced apoptosis to varying degrees. 
Expression of p53 Target Genes After Ad-p53 Infection
Immunoblots for p53 expression revealed up to a 4-fold increase in protein levels in both U87-175.4 and U87-Lux.8 infected with Ad-p53 (Fig. 4A) . U87-175.4 exhibited higher endogenous levels of p53 than did U87-Lux.8, presumably due to the expression of mutant p53 (175H). Western blot analyses were performed to examine differential expression of known p53 target genes in response to Ad-p53 infection.
Overexpression of MDM2, a negative regulator of p53, has been shown to inactivate wild-type p53 and prevent apoptosis (Chen et al., 1996) . We sought to determine if irregular expression of MDM2 was responsible for resistance to p53-mediated apoptosis in our system. Western blot analysis indicated that similar levels of MDM2 were detected in both U87-Lux.8 and U87-175.4 up to 96 h after infection, whereas undetectable levels of MDM2 were noted in the mock and AdDE1-infected control cells (Fig. 4B) . These levels were consistent with those recorded after overexpression of p53 through DNA damage or apoptotic insult . Although allelic exclusion or mutations in MDM2 have been associated with abnormalities in p53 in numerous cell lines (Cheng et al., 1995) , it appears that differential MDM2 expression was not responsible for the differences in apoptotic response demonstrated by U87-Lux.8 and U87-175.4.
Overexpression of BCL2 has been shown to inhibit p53-mediated apoptosis after various apoptotic stimuli. We examined whether there were alterations in BCL2 protein levels involved in Ad-p53-induced apoptosis in U87-175.4. Endogenously, U87-Lux.8 and U87-175.4 express comparable levels of BCL2 as shown in mockand AdDE1-infected samples (Fig. 5) . However, BCL2 expression in U87-Lux.8 cells decreased at 48 h post-Adp53 infection and were sustained at such a level until 96 h (Fig. 5) . In contrast, after Ad-p53 infection, BCL2 levels in U87-175.4 cells appeared to increase modestly at 48 h and 72 h with respect to the 24 h level, yet were not signi cantly greater than mock or AdDE1 samples. These ndings, however, did not fully account for cell viability or TUNEL results and suggested that the involvement of other BCL2 family members may contribute to inhibiting apoptosis in the wild-type p53 glioma . Therefore, Bcl-X L protein expression was examined under the same conditions. No differences in expression were detected between uninfected and Adp53-infected cells (data not shown). Similarly, there was no indication that differences in BAX protein levels measured after Ad-p53 infection were responsible for the observed differences in apoptotic response displayed by U87-Lux.8 and U87-175.4. The role of other BCL2 family members in this model system remains to be determined and is currently under investigation. p21 WAF1/CIP1 is a key cell cycle regulator that mediates growth arrest by inhibiting the action of G 1 cyclin-dependent kinases (Waga et al., 1994) . As a downstream target of p53, p21 WAF1/CIP1 levels can be induced after Ad-p53 infection in glioma cell lines regardless of their p53 status (GomezManzano et al., 1997). We sought to determine whether Ad-p53 infection induces p21 WAF1/CIP1 expression and promotes cell cycle arrest in U87-Lux.8 and U87-175.4 cells. Western blot analysis showed higher levels of p21 WAF1/CIP1 expression in U87-Lux.8 cells than in U87-175.4 cells during 24-72 h postinfection (Fig. 5) . Protein levels appeared to decrease in both cell lines at 96 h postinfection. Decreases in p21 WAF1/CIP1 expression correlated well with the concomitant reduction of G 1 cell population observed in cell cycle analysis (Fig. 5 and Table 1 ).
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Neuro-Oncology n A P R I L 2 0 0 1 117 Fig. 2 . Viability assay: Effects of exogenous p53 on the growth of U87-Lux.8 and U87-175.4 cells. The cells were plated at low density and were infected with AdDE1 or Ad-p53 for 96 h before being assessed for their viability by using trypan blue exclusion dye. The number of viable cells displayed includes the mean ± SD of triplicate experiments, and P values were determined by t-test analyses between AdDE1 and Ad-p53 data. SDs of U87-175.4 experiments were too small to appear in the graph. The assay was repeated a minimum of 3 times. 
PARP Cleavage Was Evident in U87-175.4 Cells upon p53-Induced Apoptosis
Involvement of caspases in cell death is a hallmark for apoptosis. We examined whether overexpression of p53 in both U87-Lux.8 and U87-175.4 cells would lead to differential expression of a central caspase, CPP32 (caspase-3), and subsequently apoptosis in U87-175.4 cells. Western blot analysis was used to measure the levels of the proform of CPP32 as an indicator of caspase activation. In the U87-Lux.8 cell line, CPP32 levels increased at 48 h post Ad-p53 infection compared with controls (Fig.  6A) . The signi cance of the accumulation of CPP32 proform is unclear. However, U87-Lux.8 cells do not undergo apoptosis when assayed longer than 96 h post-Ad-p53 infection (data not shown). Interestingly, no changes in the proform of CPP32 were detected in Ad-p53-infected U87-175.4 cells (Fig. 6A) . Characteristic with the onset of apoptosis is the cleavage of enzymes that are responsible for DNA fragmentation. PARP functions as a DNA repair enzyme and is cleaved by caspases during apoptosis. PARP is a downstream target of multiple caspases, including caspase-2, CPP32, caspase-7, and caspase-9 (King et al., 1998) . We examined whether the apoptotic event detected in U87-175.4 cells involved PARP cleavage. Western blot analysis for the identi cation of PARP cleavage was performed using C2-10 anti-PARP antibody. The 85-kDa cleaved product can be detected as early as 48 h after Ad-p53 infection and is visible for up to 96 h after infection (Fig.  6B) . However, in the mock-infected and AdDE1-infected controls, a cleaved product of PARP was also detected, yet to a lesser degree. A similar analysis was performed for U87-Lux.8 cells. Western blot analysis indicates that no cleavage product corresponding to the molecular mass of 85 kDa was evident in U87-Lux.8 cells infected with Ad-p53 virus (Fig. 6B) . Furthermore, in contrast to what was observed in U87-175.4 cells, no basal level of the 85-kDa protein was detected in the mock-and AdDE1-infected controls for U87-Lux.8 cells.
Enzymatic Activity of Caspases After Ad-p53 Infection
To further con rm the apoptotic induction by p53 in U87-175.4, we performed a more sensitive assay by measuring the activity of several caspases. Both U87-Lux. A B Cells (2 3 10 6 ) were infected with 100 MOI of AdDE1 or Ad-p53 for 24 h or 72 h. Mock infection with medium was used as a control. After infection, cells were harvested and and U87-175.4 cell lines were mock-infected, AdDE1 infected, or Ad-p53 infected for 96 h, and cell extracts were assayed for caspase-1, -2, and -3 activity using a commercial kit (R&D Systems, Minneapolis, Minn.). There was no induction of caspase-1 activity in both cell lines after Ad-p53 infection. However, U87-175.4 cells exhibited approximately a 2-fold induction of caspase-2 and -3 enzymatic activity after Ad-p53 infection compared with AdDE1-infected extracts (Fig. 7) . A minimal induction of both caspase-2 and caspase-3 activities was observed in U87-Lux.8 cells after Ad-p53 infection. Furthermore, induction of caspase-2 and caspase-3 enzymatic activity in U87-175.4 correlated with TUNEL and cell viability results.
Discussion
Current ideology aims to use gene therapy (Fujiwara et al., 1996) or synthetic peptides (Hupp et al., 1995) to restore wild-type p53 function in cells harboring a mutant p53 protein or those that have defective p53 pathways. Although some success with this approach has been achieved, cell types remain that are nonresponsive to these forms of therapy. Despite the ongoing gene therapy trial using Ad-p53 for glioma patients, the underlying mechanism of differential response to apoptotic induction after Ad-p53 infection is unclear. In this study, we sought to investigate the importance of p53 status in response to Ad-p53-induced apoptosis. We hypothesized that the introduction of a mutant p53 into a wild-type p53-containing cell line would sensitize the cells to Adp53-induced apoptosis. Our results demonstrated that p53 status in glioma cells is integral to determining cellular fate after Ad-p53 insult. Isogenic mutant cell lines of U87-Lux.8 and U87-175.4 have been used to demonstrate that the overexpression of a mutant p53 in a wild-type p53-expressing cell line alters its radiosensitive phenotype (Yount et al., 1996) . Using these cell lines, we demonstrated that the reintroduction of a functional wild-type p53 via adenoviral-mediated gene transfer into U87-175.4 cells results in an apoptotic-sensitive phenotype similar to cell lines with endongenous p53 mutations. Interestingly, other p53 mutants such as 248W and 273H also exert similar effects as 175H, albeit less effectively. Several studies support the active role of multiple mutant p53 genes in transcription and protein-protein interactions (Friedlander et al., 1996; Selivanova et al., 1997) . Evidence by Zhang et al. (1993) indicates that both 273 and 175 mutants can retain their DNA binding and transcriptional activity. Alternatively, Hachiya et al. (1994) have demonstrated that both the 175 and 248 mutants, but not 273, can suppress wild-type p53 transcriptional activity when co-expressed in cells. Because the extent of apoptotic induction elicited by these p53 mutants varied, the effect on apoptotic response by these mutants may re ect their differential binding activity to the p53-responsive element. arf result in a multitude of destabilized pathways and may contribute to the sensitivity to Ad-p53. In addition, the formation of wild-type p53 and mutant p53 heterodimers may affect transcriptional regulation of key apoptotic genes and account for the phenotype of the isogenic cell lines. These heterotetramers may preferentially activate genes or interfere with regulators that induce apoptosis. We determined that the expression of p53 was elevated in both U87-Lux.8 and U87-175.4 cells after Adp53 infection. Therefore, the apoptosis observed in U87-175.4 cells was not a consequence of differential p53 expression, rather the difference in apoptotic response may re ect differences in the transcription of p53 target genes. With regard to this possibility, both cell lines expressed elevated levels of p21 WAF1/CIP1 after Ad-p53 infection, suggesting that the p53/p21 WAF1/CIP1 pathway was not compromised in either cell line. Additionally, the levels of MDM2, a negative regulator of p53 function, were unaltered in these 2 cell lines after Ad-p53 infection. The potential involvement of both BCL2 and BAX was also examined. After Ad-p53 infection, BCL2 levels appeared to decrease in U87-Lux.8 cells over time, in contrast with those that remained unchanged in U87-175.4-infected cells. No noticeable changes of BAX expression in either U87-Lux.8 or U87-175.4 were evident. Results of BCL2 and BAX expression in the isogenic mutant cell lines contradict the results from cell viability and TUNEL assays showing that U87-Lux.8 cells are resistant to p53-induced apoptosis.
One of the most important downstream mediators of the caspase cascade is CPP32. Differences in the endogenous levels of CPP32 were evident in the 2 cell lines studied whereby U87-175.4 cells display higher levels of the pro-CPP32 protein than did U87-Lux.8 cells. Interestingly, levels of the proform of the enzyme increased after Ad-p53 infection in U87-Lux.8 but not in U87-175.4 cells. It is likely that this increase is a result of the inability of cellular machinery to activate CPP32 and contributes to its apoptotic insensitive phenotype. In contrast, the levels of pro-CPP32 in Ad-p53-infected U87-175.4 cells remain constant and may be due to continual processing of the procaspase. A more sensitive enzymatic assay for caspase activity revealed that several caspases, including caspase-2 and caspase-3, were activated after Ad-p53 infection on U87-175.4 cells. These results point toward the involvement of complex proteolytic systems whereby a combination of proteases, cofactors, inhibitors, feedback loops, and thresholds act in concert to execute an apoptotic signal (Thornberry and Lazebnik, 1998) . Finally, the DNA repair enzyme PARP was cleaved in U87-175.4 cells but not in U87-Lux.8 cells after Ad-p53 infection. These data con rm that PARP cleavage is indeed an active part of p53-mediated apoptosis in glioma and includes the activation of multiple caspases. In this study we examined the effect of Ad-p53 on the expression of only a few key target genes. It is likely that other genes may contribute to the sensitization of U87-175.4 cells to p53-induced apoptosis. Efforts to employ techniques such as the DNA array, for the pro ling of multiple gene expression in response to Ad-p53, are under way.
Taken together, our results demonstrate the importance of p53 status in governing cellular fate after Adp53 treatment. The ability to alter an apoptotic-resistant phenotype indicates that intrinsic apoptotic pathways are functional in U-87 MG cells and can be reinitiated upon the change in p53 status. Understanding p53 pathways and the mediators of the apoptotic response in glioma will signi cantly facilitate the design of novel antitumor strategies. Gaining insight into the intricate mechanisms of resistance in glioma will enable us to pinpoint the genes or pathways to target for radiation or gene therapy.
